<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2018-07-11" updated="2019-12-02">
  <drugbank-id primary="true">DB14505</drugbank-id>
  <drugbank-id>DBSALT002513</drugbank-id>
  <name>Sodium borate</name>
  <description/>
  <cas-number>1330-43-4</cas-number>
  <unii>8191EN8ZMD</unii>
  <average-mass>201.219</average-mass>
  <monoisotopic-mass>201.981163568</monoisotopic-mass>
  <groups>
    <group>approved</group>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32449</ref-id>
        <pubmed-id>21774671</pubmed-id>
        <citation>Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME: Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt). 2011 Aug;20(8):1245-55. doi: 10.1089/jwh.2010.2708. Epub 2011 Jul 20.</citation>
      </article>
      <article>
        <ref-id>A32450</ref-id>
        <pubmed-id>1432568</pubmed-id>
        <citation>Teshima D, Morishita K, Ueda Y, Futagami K, Higuchi S, Komoda T, Nanishi F, Taniyama T, Yoshitake J, Aoyama T: Clinical management of boric acid ingestion: pharmacokinetic assessment of efficacy of hemodialysis for treatment of acute boric acid poisoning. J Pharmacobiodyn. 1992 Jun;15(6):287-94.</citation>
      </article>
      <article>
        <ref-id>A32457</ref-id>
        <pubmed-id>19059942</pubmed-id>
        <citation>De Seta F, Schmidt M, Vu B, Essmann M, Larsen B: Antifungal mechanisms supporting boric acid therapy of Candida vaginitis. J Antimicrob Chemother. 2009 Feb;63(2):325-36. doi: 10.1093/jac/dkn486. Epub 2008 Dec 4.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L2140</ref-id>
        <title>BORIC ACID - National Library of Medicine HSDB Database- Toxnet - NIH</title>
        <url>https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+1432</url>
      </link>
      <link>
        <ref-id>L2141</ref-id>
        <title>Boric Acid - National Toxicology Program - NIH</title>
        <url>https://ntp.niehs.nih.gov/ntp/htdocs/lt_rpts/tr324.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>No FDA- or EMA-approved therapeutic indications on its own.</indication>
  <pharmacodynamics>Boric acid exhibits minimal bacteriostatic and antifungal activities [L2140]. Boric acid is likely to mediate antifungal actions at high concentrations over prolonged exposures [A32457]. </pharmacodynamics>
  <mechanism-of-action>Information regarding the mechanism of action of boric acid in mediating its antibacterial or antifungal actions is limited. Boric acid inhibits biofilm formation and hyphal transformation of _Candida albicans_, which are critical virulence factors [A32457]. In addition, arrest of fungal growth was observed with the treatment of boric acid [A32457].</mechanism-of-action>
  <toxicity>Acute oral LD50 is 2660 mg/kg in rat [MSDS]. Individuals are likely to be exposed to boric acid from industrial manufacturing or processing. Local tissue injury from boric acid exposure is likely due to caustic effects. Systemic effects from boric acid poisoning usually occur from multiple exposures over a period of days and involve gastrointestinal, dermal, CNS, and renal manifestations. Gastrointestinal toxicity include persistent nausea, vomiting, diarrhea, epigastric pain, hematemesis, and blue-green discoloration of the feces and vomit [L2140]. Following the onset of GI symptoms, a characteristic intense generalized erythroderma follows [L2140]. Management of mild to moderate toxicity should be supportive. In case of severe toxicity, dialysis may be required in addition to supportive treatment. </toxicity>
  <metabolism>No metabolic pathways reported. </metabolism>
  <absorption>Boric acid is well absorbed from the gastrointestinal tract, open wounds, and serous cavities but displays limited absorption in intact skin [L2140]. Following intraperitoneal injection in mice, the peak concentration was reached in about 1.0-1.5 hr in the brain whereas the value was 0.5 hr in other tissues [L2140]. </absorption>
  <half-life>According to human cases of poisoning, the elimination half-life of boric acid ranges from 13 to 24 hours [A32450, L2140].</half-life>
  <protein-binding>No protein binding reported. </protein-binding>
  <route-of-elimination>Regardless the route of administration, boric acid predominantly undergoes rapid renal excretion of &gt;90% of total administered dose as unchanged form. Small amounts are also excreted into sweat, saliva, and feces. Following administration as ointment, urinary excretion of boric acid accounted for only 1% of the administered dose [L2140].</route-of-elimination>
  <volume-of-distribution>Volume of distribution ranges from 0.17 to 0.5 L/kg in humans, where large amounts of boric acid are localized in brain, liver, and kidney [L2140].</volume-of-distribution>
  <clearance>A case report of acute boric acid poisoning following oral ingestion of 21 g of boric acid presents the total body clearance of 0.99 L/h before hemodialysis [A32450].</clearance>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002514</drugbank-id>
      <name>Sodium borate decahydrate</name>
      <unii>91MBZ8H3QO</unii>
      <cas-number>1303-96-4</cas-number>
      <inchikey>CDMADVZSLOHIFP-UHFFFAOYSA-N</inchikey>
      <average-mass>381.36</average-mass>
      <monoisotopic-mass>382.086808</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Borax</synonym>
    <synonym language="english" coder="">Sodium borate anhydrous</synonym>
  </synonyms>
  <products>
    <product>
      <name>Collyre Hygienique Soker</name>
      <labeller>Produits Francais Labs Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00425745</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1978-12-31</started-marketing-on>
      <ended-marketing-on>1997-05-30</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eye Eze</name>
      <labeller>Pharmavite Laboratories (1987) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00581836</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1958-12-31</started-marketing-on>
      <ended-marketing-on>2006-07-27</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Glycothymoline</name>
      <labeller>Glendale Agencies</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00110760</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>1996-11-29</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Ma Ying Long Hemorrhoidal</name>
      <labeller>Trifecta Pharmaceuticals Usa, Llc.</labeller>
      <ndc-id/>
      <ndc-product-code>69396-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Miel Rosada</name>
      <labeller>Dannso corp./d.b.a. Essential Products</labeller>
      <ndc-id/>
      <ndc-product-code>70242-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Occu-cal Drops</name>
      <labeller>Produits Francais Labs Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00540935</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>1997-05-30</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Occu-cal Lotion</name>
      <labeller>Produits Francais Labs Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00540927</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>1997-05-30</ended-marketing-on>
      <dosage-form>Lotion</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sel De Perou</name>
      <labeller>Produits Francais Labs Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00166081</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1930-12-31</started-marketing-on>
      <ended-marketing-on>1997-05-30</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sodium Borate</name>
      <labeller>Lab Valmo EnregistrÉ, Division Of Technilab Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00458988</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>1999-09-17</ended-marketing-on>
      <dosage-form>Powder</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Thunas Eye Drops</name>
      <labeller>Thuna Herbal Remedies Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00457345</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>2002-10-16</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Trimo San Deodorant Vaginal Jelly</name>
      <labeller>Milex Products Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00484768</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>2005-07-25</ended-marketing-on>
      <dosage-form>Jelly</dosage-form>
      <strength/>
      <route>Vaginal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Miel Rosada</name>
      <ingredients>Glycerin + Sodium borate</ingredients>
    </mixture>
    <mixture>
      <name>Ma Ying Long Hemorrhoidal</name>
      <ingredients>Amber + Borneol + Bos taurus gallstone + Moschus berezovskii musk sac resin + Pearl (hyriopsis cumingii) + Sodium borate + Zinc carbonate</ingredients>
    </mixture>
    <mixture>
      <name>Sodium Borate</name>
      <ingredients>Sodium borate</ingredients>
    </mixture>
    <mixture>
      <name>Trimo San Deodorant Vaginal Jelly</name>
      <ingredients>Boric acid + Oxyquinoline + Sodium borate</ingredients>
    </mixture>
    <mixture>
      <name>Thunas Eye Drops</name>
      <ingredients>Boric acid + Sodium borate</ingredients>
    </mixture>
    <mixture>
      <name>Eye Eze</name>
      <ingredients>Boric acid + Sodium borate</ingredients>
    </mixture>
    <mixture>
      <name>Glycothymoline</name>
      <ingredients>Benzoic acid + Sodium borate</ingredients>
    </mixture>
    <mixture>
      <name>Sel De Perou</name>
      <ingredients>Sodium borate + Sodium carbonate</ingredients>
    </mixture>
    <mixture>
      <name>Collyre Hygienique Soker</name>
      <ingredients>Boric acid + Sodium borate</ingredients>
    </mixture>
    <mixture>
      <name>Occu-cal Lotion</name>
      <ingredients>Boric acid + Phenylephrine + Sodium borate</ingredients>
    </mixture>
    <mixture>
      <name>Occu-cal Drops</name>
      <ingredients>Boric acid + Phenylephrine + Sodium borate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids</category>
      <mesh-id>D000143</mesh-id>
    </category>
    <category>
      <category>Acids, Noncarboxylic</category>
      <mesh-id>D000148</mesh-id>
    </category>
    <category>
      <category>Anions</category>
      <mesh-id>D000838</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Boric Acids</category>
      <mesh-id>D001888</mesh-id>
    </category>
    <category>
      <category>Boron Compounds</category>
      <mesh-id>D001896</mesh-id>
    </category>
    <category>
      <category>Electrolytes</category>
      <mesh-id>D004573</mesh-id>
    </category>
    <category>
      <category>Ions</category>
      <mesh-id>D007477</mesh-id>
    </category>
    <category>
      <category>Ophthalmologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sensory Organs</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Ointment</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Lotion</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Jelly</form>
      <route>Vaginal</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="S01AX07">
      <level code="S01AX">Other antiinfectives</level>
      <level code="S01A">ANTIINFECTIVES</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.68</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>disodium bicyclo[3.3.1]tetraboroxane-3,7-bis(olate)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>disodium bicyclo[3.3.1]tetraboroxane-3,7-bis(olate)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>201.219</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>201.981163568</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Na+].[Na+].[O-]B1OB2OB([O-])OB(O1)O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>B4Na2O7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/B4O7.2Na/c5-1-7-3-9-2(6)10-4(8-1)11-3;;/q-2;2*+1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>UQGFMSUEHSUPRD-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>92.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>9.64</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>11.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>8.35</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>6996</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>8395345</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Borax</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>